- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04047550
Respiratory Control and Narcotic Effects
Respiratory Control and Prevention of Opioid-Induced Respiratory Depression After Surgery
Study Overview
Status
Intervention / Treatment
Detailed Description
The study aims to test the following hypotheses:
Low respiratory drive is predictive of opioid-induced respiratory depression as defined by end-tidal PCO2 (PETCO2) >50 mmHg, ventilation <20% below baseline or pulse oximeter reading (SpO2) <90%.
Respiratory depression is more likely during certain sleep stages, specifically slow wave sleep.
Respiratory Drive. Before surgery each patient's hypercapnic ventilatory response under conditions of mild hypoxia and mild hyperoxia. Using this technique, the patient first voluntarily hyperventilates to a PETCO2 value of 20-25 mmHg, then undergoes a rebreathing test allowing the PCO2 to rise to 55-60 mmHg while end-tidal PO2 (PETO2) is maintained at 150 mmHg. The procedure is then repeated with PETO2 clamped at 50 mmHg. Parameters derived from this method include slopes of the ventilatory response during hyperoxia and hypoxia. The slope during mild hypoxia is felt to be an index of peripheral chemoreceptor function, while the hyperoxic slope is more indicative of central respiratory drive.
These two maneuvers will then be repeated during an infusion of the ultra-short acting opioid, remifentanil. Remifentanil will be administered to achieve a specified effect site concentration selected to produce a 30% decrease in ventilation using a standard pharmacokinetic model implemented on a widely-used shareware program (TIVATrainer, www.eurosaver.eu). Recovery from ventilatory depression occurs within 10 minutes of discontinuation of the infusion.
Sleep Test. During a night before surgery a sleep test based on peripheral arterial tone will be performed at home (WatchPAT™, Itamar Medical, Franklin, MA) and will provide a formal measure of obstructive sleep apnea. This test requires only a device mounted on a finger that assesses SpO2 and peripheral tone, and an accelerometer on the chest to assess breathing movements. Respiratory indices calculated using this technology correlates with those calculated from standard polysomnography. The same testing will be used postoperatively from the time the patient enters the post anesthesia care unit (PACU) until the following morning. Recording of the same variables will then continue: inter-breath interval, respiratory minute volume (using an electrical impedance device: ExSpiron™, Respiratory Motion, Waltham, MA), abdominal strain gauge recording, transcutaneous PCO2 (SenTec, Fenton, MO), and sleep measures. The data stream will then be divided into 5 minute epochs. During each epoch the sleep state (awake, stages 1-4 slow wave sleep, rapid eye movement (REM) sleep), opioid consumption, respiratory variables and apnea/hypopnea index (AHI) will be assessed. Subjects will have the option to opt in or out of participation in the overnight sleep study.
Long-Term Pulse Oximetry. For the entire postoperative period until discharge we will record opioid consumption and SpO2/heart rate using a wrist oximeter (WristOx™, Nonin Medical, Plymouth, MN).
Postoperative parameters of respiratory depression include hypercapnia (transcutaneous PCO2), hypoxemia, apneas, low respiratory minute volume and sleep state.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
18 years of age or older, undergoing major abdominal or urological surgery requiring at least one overnight hospital stay
Exclusion Criteria:
Pregnancy Adverse reaction to remifentanil Opioid-use within the past month Dependency on supplemental oxygen Brain injury in the past year Coronary artery disease Sickle cell disease.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid related respiratory depression (OIRD) frequency
Time Frame: From the arrival of the patient in the post anesthesia care unit until the first postoperative morning
|
A respiratory event is defined as one or more of the following:
Events must last 1 minute or more to be counted. Events occurring within one minute of each are combined as a single event. |
From the arrival of the patient in the post anesthesia care unit until the first postoperative morning
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of OIRD during specific sleep stages
Time Frame: From the arrival of the patient in the post anesthesia care unit until the first postoperative morning
|
OIRD as defined in the primary outcome, as a function of sleep stage postoperatively, as measured using the WatchPAT™ (Itamar Medical, Franklin, MA)
|
From the arrival of the patient in the post anesthesia care unit until the first postoperative morning
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00046973
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventilatory Depression
-
Charles University, Czech RepublicMilitary University Hospital, PragueRecruitingVentilatory Depression | Sedation ComplicationCzechia
-
Hollister IncorporatedTerminatedRespiratory Failure | Ventilatory Depression | Respiratory DepressionUnited States
-
Tampere University HospitalWithdrawn
-
Erasme University HospitalUnknownVentilatory Depression | Oocyte Retrieval | Sedation, ConsciousBelgium
-
Stanford UniversityCompletedVentilatory Depression | Postoperative Respiratory ComplicationUnited States
-
Assistance Publique - Hôpitaux de ParisNeuroresp, Reference centre Syndrome d'OndineRecruitingExternal Mechanical Ventilatory SupportFrance
-
Northwestern UniversityWithdrawnPain | Ventilatory DepressionUnited States
-
University of MalayaUnknownVentilatory Depression
-
Stanford UniversityRecruitingVentilatory Depression | Postoperative Respiratory FailureUnited States
-
Hadassah Medical OrganizationOridionUnknownVentilatory Status of Deeply Sedated ERCP PatientsIsrael
Clinical Trials on Ventilatory chemosensitivity
-
University of Turin, ItalyActive, not recruiting
-
University Hospital, MontpellierCompletedCritical Illness | Intensive Care | Mechanical Ventilation | Ventilation WeaningFrance
-
Centre Hospitalier Universitaire Saint PierreUniversité Libre de BruxellesCompletedHypoxia | Hypercapnia | Hyperventilation SyndromeBelgium
-
University Hospital, MontpellierCompleted
-
Tampere University HospitalWithdrawn
-
Poitiers University HospitalResMedCompletedObstructive Sleep Apnea | Sudden Hearing LossFrance
-
Hospices Civils de LyonUnknown
-
University Hospital Inselspital, BerneWithdrawnRespiratory Failure
-
Pierre and Marie Curie UniversityCompletedNon-Invasive Positive-Pressure VentilationFrance